Latest Pneumococcal conjugate vaccine Stories
BEIJING, Jan. 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
NEW YORK, Dec.
NEW YORK, Dec. 12, 2010 /PRNewswire/ -- Pfizer Inc.
A new study suggests that preterm infants may not be fully protected against invasitve pneumococcal disease under the current United Kingdom immunization schedule.
A Pneumonia Report Card released today by the International Vaccine Access Center (IVAC) on behalf of the Global Coalition against Child Pneumonia reveals where urgent efforts are needed to reach target levels of coverage for the life-saving interventions that can prevent, protect against and treat pneumonia in children.
Contrary to current thinking, the group of serotypes of Streptococcus pneumoniae responsible for most invasive pneumococcal disease worldwide is conserved across regions.
Infants who received heptavalent pneumococcal conjugate vaccination (PCV-7) at 2, 4, and 11 months were more likely than unvaccinated controls to have nasopharyngeal (in the nasal passages and upper part of the throat behind the nose) acquisition of pneumococcal serotype 19A, a leading cause of respiratory pneumococcal disease.
The number of children admitted to English hospitals with bacterial pneumonia decreased by a fifth in the 2 years following the introduction of a vaccine to combat the disease.
SWIFTWATER, Pa., Aug. 26 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S.
NEW YORK, Aug.
- totally perplexed and mixed up.